**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 58726

**Manuscript Type:** ORIGINAL ARTICLE

***Case Control Study***

**Fatty liver is an independent risk factor for gallbladder polyps**

Ahn DW *et al*. Fatty liver and gallbladder polyps

Dong-Won Ahn, Ji Bong Jeong, Jinwoo Kang, Su Hwan Kim, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, Sohee Oh, Soon Ho Yoon, Sang Joon Park, Doo Hee Lee

**Dong-Won Ahn, Ji Bong Jeong, Jinwoo Kang, Su Hwan Kim, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee,** Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, South Korea

**Dong-Won Ahn, Ji Bong Jeong, Jin Woo Kang, Su Hwan Kim, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee,** Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul 07061, South Korea

**Sohee Oh,** Department of Biostatistics, Medical Research Collaborating Center, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul 07061, South Korea

**Soon Ho Yoon, Sang Joon Park,** Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, South Korea

**Doo Hee Lee,** Department of Research and Development, MEDICALIP Co. Ltd., Seoul 03127, South Korea

**Author contributions:** Ahn DW planned and design the study, performed acquisition, analysis, and interpretation of data, drafted the manuscript, made critical revisions related to important intellectual content, and approved the manuscript; Jeong JB planned and design the study, performed acquisition, analysis, and interpretation of data, made critical revisions related to important intellectual content, and approved the manuscript; Kang J and Kim SH performed acquisition, analysis, and interpretation of data; Oh S, Kim JW, Kim BG and Lee KL performed analysis and interpretation of data, made critical revisions related to important intellectual content, and approved the manuscript; Yoon SH performed imaging analysis, reviewed imaging of computed tomography, and finally confirmed the results of the review; Park SJ and Lee DH performed imaging analysis and reviewed imaging of computed tomography.

**Corresponding author: Ji Bong Jeong, MD, PhD, Associate Professor,** Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20 Borame-ro 5-gil, Dongjak-gu, Seoul 07061, South Korea. jibjeong@snu.ac.kr

**Received:** August 11, 2020

**Revised:** October 28, 2020

**Accepted:** November 13, 2020

**Published online:** November 28, 2020

**Abstract**

BACKGROUND

Gallbladder polyps (GBPs) are known to be associated with obesity and metabolic diseases. However, to date, the relationship between GBPs and abnormal body fat distribution, such as fatty liver, visceral obesity, or sarcopenia, has not yet been established.

AIM

To evaluate whether GBPs are associated with fatty liver, visceral obesity, or sarcopenia.

METHODS

We retrospectively reviewed the medical records of subjects who underwent various laboratory tests, body composition measurement with a non-invasive body composition analyzer, and abdominal ultrasonography during health checkups. A total of 1405 subjects with GBPs were compared with 2810 age- and sex-matched controls.

RESULTS

The mean age of the subjects was 46.8 ± 11.7 years, and 63.8% were male. According to multiple logistic regression analysis, the presence of fatty liver [odds ratio (OR) 1.413; 95% confidence interval (CI) 1.218-1.638; *P* < 0.001] was an independent risk factor for GBP, together with low levels of alanine aminotransferase (OR 0.993; 95%CI 0.989-0.996; *P* < 0.001). Additionally, fatty liver showed both independent (OR 1.629; 95%CI, 1.335-1.988; *P* < 0.001) and dose-dependent (moderate to severe fatty liver; OR 2.137; 95%CI, 1.662-2.749; *P* < 0.001) relationship with large GBPs (≥ 5 mm). The presence of sarcopenia and high visceral fat area were not significantly associated with GBPs.

CONCLUSION

Fatty liver was found to be closely associated with GBPs irrespective of sarcopenia and visceral obesity.

**Key Words:** Gallbladder polyp; Fatty liver; Sarcopenia; Visceral obesity; Risk factors; Body fat distribution

**Citation:** Ahn DW, Jeong JB, Kang JW, Kim SH, Kim JW, Kim BG, Lee KL, Oh S, Yoon SH, Park SJ, Lee DH. Fatty liver is an independent risk factor for gallbladder polyps. *World J Gastroenterol* 2020; 26(44): 6979-6992

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i44/6979.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i44.6979

**Core Tip:** This is a retrospective cross-sectional study evaluating relationship between gallbladder polyp (GBP) and various body compositions including body fat distribution by using data from routine health checkups. According to this study, only fatty liver was an independent risk factor for GBP among the body compositions; visceral obesity and sarcopenia were not associated with GBP. There was a dose-dependent relationship between GBP and fatty liver especially in the larger GBP group. The results of this study suggest that careful assessment of GBP using abdominal ultrasonography be considered in patients with severe fatty liver.

**INTRODUCTION**

Gallbladder polyps (GBPs) are one of the most common biliary diseases and a major public health problem in many countries. The prevalence of GBP varies according to race and region[1] and diagnosis of GBP has been increasing in recent years due to the widespread use of ultrasonography (US) in routine health checkups[2]. Although benign cholesterol polyps are the most common type of GBP, accounting for 46% to 70% of all GBPs[3], some GBPs have malignant potential and the possibility of malignancy is markedly increased when the polyps are 10 mm or larger in size[2,4]. Considering the poor prognosis of advanced gallbladder cancer, it is important to detect GBPs before they reach an advanced stage.

Determination of risk factors that contribute to GBP formation would help to design clinical strategies for screening and treatment in clinical practice. According to previous studies, old age, male gender, obesity, and metabolic syndrome are known to be associated with GBP[5-9]. Some studies have investigated the relationship between GBP and abnormal body fat distribution, such as fatty liver and visceral fat[1,4,10]. However, the results of these studies have been conflicting. Furthermore, there have been no studies evaluating the relationship between GBP and sarcopenia, which is a syndrome consisting of a progressive and generalized loss of skeletal mass and strength associated with a risk of physical disability, poor quality of life, and death[11]. The aim of the present study was to determine whether the development of GBP is associated with body composition and abnormal fat distribution, such as fatty liver, visceral obesity, or sarcopenia.

**MATERIALS AND METHODS**

***Study population***

Subjects who underwent abdominal US and body composition measurement with a noninvasive body composition analyzer on the same day during a comprehensive health evaluation at Seoul National University Boramae Medical Center between January 2015 and December 2019 were enrolled in this study. After excluding subjects with a history of previous cholecystectomy, we enrolled subjects with GBP detected with abdominal US as the GBP group. Then, we enrolled age- and sex-matched subjects who were randomly selected among subjects without GBP in a ratio of 1:2 (GBP:control) as the control group. Age and sex matching was performed because both age and sex were considered important confounders in previous studies[12].

The study was conducted in accord with the Helsinki Declaration and approved by the Institutional Review Board of Seoul National University Boramae Medical Center (IRB No. 30-2020-054).

***Clinical and laboratory evaluations***

All subjects underwent basic anthropometric examination and serum chemistry testing on the same day as both abdominal US and body composition measurement with a noninvasive body composition analyzer. Serum chemistry testing was performed after an overnight (12 h) fast, and structured questionnaires were reviewed to evaluate current illness (*e.g.*, hypertension, diabetes, and metabolic syndrome) and current medications.

Body mass index (BMI) was calculated with division of weight (kg) by height squared (m2). Waist circumference was measured at the midpoint between the inferior margin of the last rib and the superior iliac crest in the horizontal plane. Hypertension was defined as a blood pressure of ≥ 130/85 mmHg. Diabetes mellitus was defined as a fasting glucose level of ≥ 126 mg/dL. Subjects taking antihypertensive or antidiabetic drugs were considered to have hypertension or diabetes. Metabolic syndrome was defined as the presence of at least three of the following five criteria from the National Cholesterol Education Program Adult Treatment Panel III: (1) waist circumference ≥ 102 cm in men and ≥ 88 cm in women; (2) triglyceride (TG) level ≥ 150 mg/dL, or with drug treatment for elevated TG level; (3) high-density lipoprotein cholesterol (HDL-C) level < 40 mg/dL in men and < 50 mg/dL in women, or with drug treatment for reduced HDL-C level; (4) blood pressure ≥ 130/85 mmHg, or with drug treatment for hypertension; and (5) fasting plasma glucose ≥ 100 mg/dL, or with drug treatment for elevated glucose[13].

***Ultrasonographic examination***

To diagnose fatty liver and GBPs, abdominal US with a 3.5 MHz convex probe (Philips iU22; Philips Healthcare, Amsterdam, The Netherlands) was performed by experienced radiologists after an overnight (10 h) fast. The radiologists performing the US were blinded to the subjects’ clinical and laboratory information.

The diagnosis of GBPs was made when immobile features appearing to arise from the mucosa were seen without an acoustic shadow in US[14]. The diagnosis of fatty liver was made when characteristic features of “bright liver” with evident contrast between the hepatic and renal parenchyma were seen in US using previously described standardized criteria[15].

The severity and degree of fatty liver was graded according to the criteria described in previous study[16]. Mild fatty liver was diagnosed when US showed slightly diffuse increase in bright homogenous echoes in the liver parenchyma, with normal visualization of the diaphragm and portal and hepatic vein borders. Moderate fatty liver was diagnosed when US showed diffuse increase in bright echoes in the liver parenchyma, with slightly impaired visualization of the peripheral portal and hepatic vein borders. Finally, severe fatty liver was diagnosed when US showed marked increase in bright echoes at a shallow depth, with impaired visualization of the diaphragm and marked vascular blurring. Moderate and severe fatty liver were combined into a single “moderate to severe” category because of the small number of cases of severe fatty liver.

***Body composition measurement***

Body composition measurements, including skeletal muscle mass and visceral fat area (VFA), were performed using an InBody 720 [direct segmental multifrequency bioelectrical impedance analysis (BIA) method; Biospace, Seoul, Korea][17], a non-invasive body composition analyzer. The subjects fasted for at least 3 h and voided immediately before the BIA. In this system, body weight, BMI, skeletal muscle mass, and VFA are automatically calculated. Appendicular skeletal muscle mass (ASM) was calculated as the sum of the lean muscle mass in the bilateral upper and lower limbs. Then, the ASM was divided by body weight (kg) and expressed as a percentage (ASM/weight, ASM%). Sarcopenia was defined as an ASM% beyond two standard deviations (SDs) below the gender-specific mean for healthy young adults according to nationwide health examinations in the Korean population (ASM% < 29.0 in men or < 22.9 in women was considered to indicate sarcopenia)[18-20]. The VFA measured by the InBody 720 was used to assess visceral obesity.

***Comparison of InBody 720 and computed tomography data***

To validate the data on skeletal muscle mass and VFA measured by the InBody 720, we investigated the correlation between the measurements taken by the InBody 720 and the measurements obtained by computed tomography (CT) in subjects who underwent both InBody 720 and CT scans on the same day. Using a CT scan, we measured the total abdominal muscle area (TAMA) and VFA at the L3 vertebral level, which showed the highest correlation with whole-body skeletal muscle and visceral fat volume in previous studies[21,22].

All abdominal CT scans were performed using a 64-slice multidetector CT scanner (Brilliance 64 scanners; Philips Healthcare, Amsterdam, The Netherlands). To measure TAMA and VFA, precontrast CT images were uploaded to commercially available segmentation software (MEDIP Deep Catch v1.0.0.0, MEDICALIP Co. Ltd., Seoul, South Korea). The software contained a 3 dimensions (3D) U-Net that automatically segments whole-body CT images into a volumetric mask of seven body compartments: skin, bone, muscle, visceral fat, subcutaneous fat, internal organs with vessels, and spinal cord. The 3D U-net was developed using approximately 40000 labeled whole-body CT images and provides an average segmentation accuracy for muscle, visceral, and subcutaneous fat of 96.8%-99.2%, 95.1%-98.9%, and 97.1%-99.7%, respectively, in internal and external validation datasets of whole-body CT scans. After automatic segmentation, the reader selected the level of the inferior endplate of L3 vertebra and extracted TAMA and VFA at the corresponding level (Figure 1). A clinically trained image analyst (DHL) reviewed and adjusted the results and finally a radiologist (SHY) confirmed the results.

***Statistical analysis***

Differences in categorical variables were analyzed using the chi-square test. Continuous variables, expressed as means ± standard deviations, were compared using Student’s *t*-test. Some of the continuous variables were categorized according to reference values in a previous study and ATP-III NCEP, as follows[4,23]: BMI (< 23 kg/m2 as normal weight, ≥ 23 kg/m2 but < 25 kg/m2 as overweight, ≥ 25 kg/m2 as obesity), waist circumference (> 90 cm *vs* ≤ 90 cm for males and > 80 cm *vs* ≤ 80 cm for females), total cholesterol (< 200, 200-240, and ≥ 240 mg/dL), TG (< 150 and ≥ 150 mg/dL), and HDL cholesterol (> 40 mg/dL *vs* ≤ 40 mg/dL for males and > 50 mg/dL *vs* ≤ 50 mg/dL for females). Age was categorized into decades (< 30, 30-39, 40-49, 50-59, 60-69, and ≥ 70 years). Because a normal range of VFA has not been defined with an absolute cutoff value to date, the variable was categorized into quartiles and the lowest quartiles of VFA were used as references.

Binary logistic regression analysis was used to determine the factors associated with GBP. First, univariable logistic regression analysis was performed, then, variables with *P* values < 0.10 in the univariable analysis were entered into backward stepwise multiple logistic regression analysis to predict the best risk factors. The results of univariable and multivariable analyses are expressed as the odds ratios (ORs) and 95% confidence intervals (95%CIs). An OR was considered to be statistically significant if the 95%CI did not include 1.0. To investigate the correlation between the InBody 720 and CT data, we conducted Pearson correlation analysis. Statistical analysis was performed with SPSS version 26.0 (IBM, Armonk, NY, United States). Statistical significance was defined as *P* values < 0.05.

**RESULTS**

***Prevalence of GBPs in healthy patients***

From January 2015 to December 2019, a total of 13702 subjects underwent health evaluation including abdominal US and body measurement performed on the same day. After excluding 204 subjects with a history of previous cholecystectomy, 13498 subjects were enrolled in this study (Figure 2). GBPs were found in 1405 subjects (10.4%); 897 out of 7335 male subjects (12.2%) and 508 out of 6163 female subjects (8.2%) had GBPs. The age distribution of the subjects with GBPs is shown in Table 1. The prevalence of GBP tended to be higher in male subjects, and the prevalence by age peaked in the 3rd decade (Table 1).

***Baseline characteristics of the study subjects***

The 1405 subjects with GBPs (GBP group) were compared with 2810 age- and sex-matched control subjects without GBPs (control group). The baseline characteristics of the study subjects (GBP group and control group) are listed in Table 2. The mean age of the subjects was 46.8 ± 11.7 years, and 63.8% were male. The rates of fatty liver and sarcopenia among the study subjects were 43.1% and 7.2%, respectively, and the mean VFA of the study subjects was 93.8 ± 36.6 cm2.

The GBP group had a higher prevalence of fatty liver (45.8% *vs* 41.7%, *P* = 0.013) and lower levels of aspartate aminotransferase (AST) (26.02 ± 17.18 *vs* 27.80 ± 15.39, *P* = 0.001) and alanine aminotransferase (ALT) (26.50 ± 22.88 *vs* 29.02 ± 22.00, *P* = 0.001). However, no significant differences were found between the two groups in the prevalence of sarcopenia, hypertension, diabetes, and metabolic syndrome. There was also no significant difference in BMI, waist circumference, or VFA between the two groups.

***Risk factors for GBPs***

We attempted to identify the risk factors for GBP. The candidate variables associated with GBP according to univariable analysis are shown in Table 3. The presence of fatty liver and sarcopenia, and the levels of AST, ALT, alkaline phosphatase (ALP), and gamma-glutamyltransferase (GGT) tended to differ between the two groups (Table 3). However, BMI, waist circumference, and visceral obesity (VFA) were not significantly associated with GBP. Multivariable analysis indicated that the presence of fatty liver (OR, 1.413; 95%CI, 1.218-1.638; *P* < 0.001) and low ALT levels (OR, 0.993; 95%CI, 0.989-0.996; *P* < 0.001) were independent risk factors for GBP (Table 4).

We next investigated whether the degree of fatty liver was associated with GBP according to polyp size (≥ 5 mm and < 5 mm). Multivariable analysis adjusted for age, gender, and candidate variables in univariable analysis revealed that fatty liver showed both independent (OR, 1.413; 95%CI, 1.218-1.638; *P* < 0.001) and dose-dependent relationship (moderate to severe fatty liver; OR 1.631; 95%CI, 1.317-2.020; *P* < 0.001) with GBP (Table 5). Furthermore, this independent and dose-dependent relationship was strengthened in the larger GBP group (moderate to severe fatty liver; OR 2.137; 95%CI, 1.662-2.749; *P* < 0.001, Table 5). In contrast, only a marginal association between the degree of fatty liver and GBP was observed in the smaller GBP group (*P* = 0.038, Table 5).

***Correlation between computed tomography and InBody 720 data***

Among a total of 13498 enrolled subjects, 361 underwent CT scans on the same day as InBody 720 measurements. So, correlation analysis was performed in these 361 subjects. ASM measured by the InBody 720 was positively correlated with TAMA measured by CT (*R* = 0.870, *P* < 0.001, Figure 3). VFA measured by the InBody 720 was also positively correlated with VFA measured by CT (*R* = 0.708, *P* < 0.001, Figure 4).

**DISCUSSION**

GBP has become one of the most common biliary tract diseases seen in clinical practice due to the widespread use of US for routine health checkups. Because some GBPs have malignant potential, it is important to detect GBPs before they reach advanced stages, and determination of risk factors for GBP has clinical significance. Many studies have investigated the risk factors of GBP and demonstrated that metabolic diseases such as dyslipidemia, glucose intolerance, and metabolic syndrome are associated with GPB[5-8]. Considering the close association between these metabolic diseases and changes in body fat distribution[1], some studies have investigated whether abnormal body fat distribution, such as visceral fat or fatty liver, is related to GBP[1,4,10]. However, those studies have produced conflicting results. Furthermore, there have been no studies evaluating the relationship between GBP and sarcopenia, which is one of the most important indicators of body composition. Thus, we conducted this cross-sectional study to validate the results of previous studies and to clarify these issues by using data from routine health checkups in large number of subjects. To the best of our knowledge, this study is the first to comprehensively evaluate the potential associations between GBP and various indicators of body composition and fat distribution, such as fatty liver, visceral obesity, and sarcopenia. The results of this study show that fatty liver is an independent risk factor for GBP, whereas visceral obesity and sarcopenia are not associated with GBP.

Sarcopenia is defined as a syndrome consisting of a progressive and generalized loss of skeletal mass and strength associated with a risk of physical disability, poor quality of life, and death[11]. Skeletal muscle is known to play a key role in the maintenance of glucose homeostasis, and a reduction in skeletal muscle mass can cause insulin resistance and metabolic dysfunction, resulting in metabolic diseases[24,25]. One previous study reported that skeletal muscle mass in the lower limbs negatively contributes to VFA in healthy men[26]. One retrospective cross-sectional study reported that visceral obesity measured by VFA is an independent risk factor for GBP[4]. Given the results of these previous studies, we hypothesized that sarcopenia and visceral obesity, together with fatty liver, would be related to GBP. However, the results of the current study with an age- and sex-matched population show that only fatty liver is an independent risk factor; we observed no association between GBP and either visceral obesity or sarcopenia. There is a discrepancy between our results and those of the above-mentioned study demonstrating a significant association between GBP and visceral obesity[4]. There are several possible explanations for this discrepancy. First, it may be partially attributable to the difference in variables used in the analyses. Fatty liver was not investigated as a possible risk factor in the previous study. Second, there was a large difference in the number of study subjects. The GBP group contained 1405 subjects in the current study, whereas there were fewer than 100 subjects in the previous study.

In the current study, the positive association between GBP and fatty liver persisted after adjustment of other variables in the multivariable analysis, whereas neither diabetes, BMI, and metabolic syndrome, which are known to be related to metabolic diseases, were associated with GBP. These results suggest that a direct association between GBP and fatty liver may exist. One previous retrospective cross-sectional study using data from routine health checkups in a large number of subjects reported similar results[1]. In that study, GBP was significantly associated with the presence and degree of fatty liver, whereas no association was observed with metabolic syndrome or visceral obesity. Given these results, the authors suggested that hepatic fat, which is anatomically close to GB fossa, might play a more important role than visceral fat[1]. More studies regarding the mechanism and pathogenesis of these direct relationships are needed.

A recent meta-analysis showed that GBP formation was not correlated with fatty liver[10]. However, among a total of 3 studies investigating the relationship between GBP and fatty liver and included in the meta-analysis, two were not age- and sex-matched; also, the definition of fatty liver was not clear in either of those two studies[27,28].

In the current study, fatty liver was found to be associated with GBP in a dose-dependent manner. Furthermore, this independent and dose-dependent relationship was strengthened in the larger GBP group. These results are in agreement with those of the abovementioned previous study[1]. It is known that possibility of adenoma is higher in large GBPs than in smaller GBPs. So, according to the results of both the current and previous studies, fatty liver may be a risk factor not only of cholesterol GBP but also of adenomatous GBP, and careful verification using abdominal US to detect adenomatous GBP, which is a premalignant lesion, may be warranted, especially in patients with severe fatty liver. However, a further prospective study with a larger number of subjects is needed to further validate and clarify these issues.

Currently, dual energy X-ray absorptiometry (DEXA) and CT are the most accurate tools for evaluating skeletal muscle mass and visceral fat[25]. In the abovementioned previous studies on the risk factors of GBP, CT was used to measure visceral fat[1,4]. However, routine use of these tools is limited in clinical practice due to associated radiation exposure. So, in the current study, the InBody 720 was used to evaluate skeletal muscle mass and visceral fat. This tool has several strengths for application in clinical practice. First, it is non-invasive and easy to use[25,29,30]. Second, previous studies have demonstrated excellent correlations between InBody 720 data and that of DEXA and CT for evaluating skeletal muscle mass and visceral fat[31-33]. Furthermore, recent studies have used the InBody 720 to assess skeletal muscle mass and to diagnose sarcopenia[25,34]. Finally, the current study showed that skeletal muscle mass and visceral fat measured with the InBody 720 were positively correlated with those measured by CT scan. According to the results of the current and previous studies, we believe that this BIA system is a valid option for assessing sarcopenia and visceral obesity in clinical practice.

The strengths and advantages of the current study are as follows. First, age and sex matching was conducted when selecting control subjects. It is well-established that the prevalence of GBP tends to increase with age and in men. Second, this study is the first to comprehensively evaluate the potential association between GBP and various indicators of abnormal body composition and fat distribution, such as fatty liver, visceral obesity, and sarcopenia. Through this comprehensive investigation, we showed an independent and dose-dependent relationship between GBP and fatty liver, especially in subjects with large GBPs. The results of this study validate those of the abovementioned previous study[1], and suggest that careful assessment of GBP using abdominal US be considered in patients with severe fatty liver.

Despite its advantages, the current study has several limitations. First, because of the cross-sectional design, it was difficult to assess the causal or temporal relationship between fatty liver and GBP. Second, the final histology of GBP could not be confirmed in the enrolled subjects with the data from routine health checkups. Third, abdominal US was used to assess the presence and severity of fatty liver. Intra- and inter-observer variability can be a problem in assessments with abdominal US; liver biopsy is the gold standard for assessment of the presence and severity of fatty liver. However, liver biopsy is an invasive procedure and routine application of this procedure is difficult in clinical practice, especially in the setting of routine health checkups. US has several advantages, including safety, low cost, sensitivity, and specificity[1,16], and has been used as a first-line imaging in both clinical practice and epidemiological studies[35]. Finally, a selection bias might be present due to the single-center design of the current study.

**CONCLUSION**

In conclusion, the current study shows that fatty liver is associated with an increased risk of GBP in a dose-dependent manner. However, we found no significant relationship between GBP and sarcopenia or visceral obesity. Further prospective and multi-center studies are needed to validate these results and to explain the pathogenesis of the relationship seen in the current study.

**ARTICLE HIGHLIGHTS**

***Research background***

The incidence of gallbladder polyps (GBPs) has been increasing in recent years. Because some GBPs have malignant potential and the prognosis of advanced gallbladder cancer is poor, it is important to detect GBPs before they reach advanced stages. Abnormal body fat distribution has received a lot of attention in clinical practice as possible risk factor for various adult diseases.

***Research motivation***

Considering the importance of early detection of GBP, determination of risk factors for GBP might have clinical significance. Although some studies have investigated the relationship between GBP and abnormal body fat distribution, those studies are not sufficient and have produced conflicting results.

***Research objectives***

In this study, we aimed to determine whether the development of GBP is associated with body fat distribution such as fatty liver, visceral obesity, or sarcopenia.

***Research methods***

This retrospective cross-sectional study was conducted using data from routine health checkups in a single tertiary center. Based on review of the medical records of subjects who underwent various laboratory tests, body composition measurement, and abdominal ultrasonography, 1405 subjects with GBPs were compared with 2810 age- and sex-matched controls.

***Research results***

Among the body fat distributions, only the presence of fatty liver was an independent risk factor for GBP [odds ratio (OR) 1.413; 95% confidence interval (CI) 1.218-1.638; *P* < 0.001). Furthermore, fatty liver showed both independent (OR 1.629; 95%CI, 1.335-1.988; *P* < 0.001) and dose-dependent (moderate to severe fatty liver; OR 2.137; 95%CI, 1.662-2.749; *P* < 0.001) relationship with large GBPs (≥ 5 mm). However, visceral obesity and sarcopenia were not significantly associated with GBP.

***Research conclusions***

Fatty liver was associated with an increased risk of GBP in a dose-dependent manner especially in larger GBPs.

***Research perspectives***

The results of our study suggest the need of careful assessment of GBP using abdominal ultrasonography in patients with severe fatty liver. Further studies are warranted to validate the results and to explain the pathogenesis of this relationship seen in our study.

**REFERENCES**

1 **Lim SH**, Kim D, Kang JH, Song JH, Yang SY, Yim JY, Chung SJ, Kim JS, Cho SH. Hepatic fat, not visceral fat, is associated with gallbladder polyps: a study of 2643 healthy subjects. *J Gastroenterol Hepatol* 2015; **30**: 767-774 [PMID: 25376159 DOI: 10.1111/jgh.12841]

2 **Dilek ON**, Karasu S, Dilek FH. Diagnosis and Treatment of Gallbladder Polyps: Current Perspectives. *Euroasian J Hepatogastroenterol* 2019; **9**: 40-48 [PMID: 31988866 DOI: 10.5005/jp-journals-10018-1294]

3 **Lee KF**, Wong J, Li JC, Lai PB. Polypoid lesions of the gallbladder. *Am J Surg* 2004; **188**: 186-190 [PMID: 15249249 DOI: 10.1016/j.amjsurg.2003.11.043]

4 **Lee JK**, Hahn SJ, Kang HW, Jung JG, Choi HS, Lee JH, Han IW, Jung JH, Kwon JH. Visceral Obesity Is Associated with Gallbladder Polyps. *Gut Liver* 2016; **10**: 133-139 [PMID: 26260756 DOI: 10.5009/gnl14506]

5 **Chen CY**, Lu CL, Chang FY, Lee SD. Risk factors for gallbladder polyps in the Chinese population. *Am J Gastroenterol* 1997; **92**: 2066-2068 [PMID: 9362194]

6 **Lim SH**, Kim DH, Park MJ, Kim YS, Kim CH, Yim JY, Cho KR, Kim SS, Choi SH, Kim N, Cho SH, Oh BH. Is Metabolic Syndrome One of the Risk Factors for Gallbladder Polyps Found by Ultrasonography during Health Screening? *Gut Liver* 2007; **1**: 138-144 [PMID: 20485630 DOI: 10.5009/gnl.2007.1.2.138]

7 **Cantürk Z**, Sentürk O, Cantürk NZ, Anik YA. Prevalence and risk factors for gall bladder polyps. *East Afr Med J* 2007; **84**: 336-341 [PMID: 17886428 DOI: 10.4314/eamj.v84i7.9589]

8 **Park EJ**, Lee HS, Lee SH, Chun HJ, Kim SY, Choi YK, Ryu HJ, Shim KW. Association between metabolic syndrome and gallbladder polyps in healthy Korean adults. *J Korean Med Sci* 2013; **28**: 876-880 [PMID: 23772152 DOI: 10.3346/jkms.2013.28.6.876]

9 **Liu HW**, Chen CY. Ovo-lactovegetarian diet as a possible protective factor against gallbladder polyps in Taiwan: A cross-sectional study. *Ci Ji Yi Xue Za Zhi* 2019; **31**: 29-34 [PMID: 30692829 DOI: 10.4103/tcmj.tcmj\_16\_18]

10 **Yamin Z**, Xuesong B, Guibin Y, Liwei L, Fei L. Risk factors of gallbladder polyps formation in East Asian population: A meta-analysis and systematic review. *Asian J Surg* 2020; **43**: 52-59 [PMID: 31109764 DOI: 10.1016/j.asjsur.2019.03.015]

11 **Cruz-Jentoft AJ**, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* 2010; **39**: 412-423 [PMID: 20392703 DOI: 10.1093/ageing/afq034]

12 **Lin WR**, Lin DY, Tai DI, Hsieh SY, Lin CY, Sheen IS, Chiu CT. Prevalence of and risk factors for gallbladder polyps detected by ultrasonography among healthy Chinese: analysis of 34 669 cases. *J Gastroenterol Hepatol* 2008; **23**: 965-969 [PMID: 17725602 DOI: 10.1111/j.1440-1746.2007.05071.x]

13 **Huang PL**. A comprehensive definition for metabolic syndrome. *Dis Model Mech* 2009; **2**: 231-237 [PMID: 19407331 DOI: 10.1242/dmm.001180]

14 **Martin E**, Gill R, Debru E. Diagnostic accuracy of transabdominal ultrasonography for gallbladder polyps: systematic review. *Can J Surg* 2018; **61**: 200-207 [PMID: 29806818 DOI: 10.1503/cjs.011617]

15 **Choi SY**, Kim D, Kim HJ, Kang JH, Chung SJ, Park MJ, Kim YS, Kim CH, Choi SH, Kim W, Kim YJ, Yoon JH, Lee HS, Cho SH, Sung MW, Oh BH. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. *Am J Gastroenterol* 2009; **104**: 1953-1960 [PMID: 19491838 DOI: 10.1038/ajg.2009.238]

16 **Saadeh S**, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. *Gastroenterology* 2002; **123**: 745-750 [PMID: 12198701 DOI: 10.1053/gast.2002.35354]

17 **Malavolti M**, Mussi C, Poli M, Fantuzzi AL, Salvioli G, Battistini N, Bedogni G. Cross-calibration of eight-polar bioelectrical impedance analysis *vs* dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21-82 years. *Ann Hum Biol* 2003; **30**: 380-391 [PMID: 12881138 DOI: 10.1080/0301446031000095211]

18 **Kim YS**, Lee Y, Chung YS, Lee DJ, Joo NS, Hong D, Song Ge, Kim HJ, Choi YJ, Kim KM. Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys. *J Gerontol A Biol Sci Med Sci* 2012; **67**: 1107-1113 [PMID: 22431554 DOI: 10.1093/gerona/gls071]

19 **Lee YH**, Kim JE, Roh YH, Choi HR, Rhee Y, Kang DR, Lim SK. The combination of vitamin D deficiency and mild to moderate chronic kidney disease is associated with low bone mineral density and deteriorated femoral microarchitecture: results from the KNHANES 2008-2011. *J Clin Endocrinol Metab* 2014; **99**: 3879-3888 [PMID: 24878040 DOI: 10.1210/jc.2013-3764]

20 **Koo BK**, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, Lee KL, Kim W. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. *J Hepatol* 2017; **66**: 123-131 [PMID: 27599824 DOI: 10.1016/j.jhep.2016.08.019]

21 **Schweitzer L**, Geisler C, Pourhassan M, Braun W, Glüer CC, Bosy-Westphal A, Müller MJ. What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults? *Am J Clin Nutr* 2015; **102**: 58-65 [PMID: 26016860 DOI: 10.3945/ajcn.115.111203]

22 **Schweitzer L**, Geisler C, Pourhassan M, Braun W, Glüer CC, Bosy-Westphal A, Müller MJ. Estimation of Skeletal Muscle Mass and Visceral Adipose Tissue Volume by a Single Magnetic Resonance Imaging Slice in Healthy Elderly Adults. *J Nutr* 2016; **146**: 2143-2148 [PMID: 27581576 DOI: 10.3945/jn.116.236844]

23 **Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults**. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; **285**: 2486-2497 [PMID: 11368702 DOI: 10.1001/jama.285.19.2486]

24 **Abdul-Ghani MA**, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. *J Biomed Biotechnol* 2010; **2010**: 476279 [PMID: 20445742 DOI: 10.1155/2010/476279]

25 **Park YS**, Kim JW, Kim BG, Lee KL, Lee JK, Kim JS, Koh SJ. Sarcopenia is associated with an increased risk of advanced colorectal neoplasia. *Int J Colorectal Dis* 2017; **32**: 557-565 [PMID: 28013337 DOI: 10.1007/s00384-016-2738-8]

26 **Yagi S**, Kadota M, Aihara KI, Nishikawa K, Hara T, Ise T, Ueda Y, Iwase T, Akaike M, Shimabukuro M, Katoh S, Sata M. Association of lower limb muscle mass and energy expenditure with visceral fat mass in healthy men. *Diabetol Metab Syndr* 2014; **6**: 27 [PMID: 24571923 DOI: 10.1186/1758-5996-6-27]

27 **Yang HL**, Kong L, Hou LL, Shen HF, Wang Y, Gu XG, Qin JM, Yin PH, Li Q. Analysis of risk factors for polypoid lesions of gallbladder among health examinees. *World J Gastroenterol* 2012; **18**: 3015-3019 [PMID: 22736927 DOI: 10.3748/wjg.v18.i23.3015]

28 **Xu Q**, Tao LY, Wu Q, Gao F, Zhang FL, Yuan L, He XD. Prevalences of and risk factors for biliary stones and gallbladder polyps in a large Chinese population. *HPB (Oxford)* 2012; **14**: 373-381 [PMID: 22568413 DOI: 10.1111/j.1477-2574.2012.00457.x]

29 **Jaffrin MY**, Morel H. Body fluid volumes measurements by impedance: A review of bioimpedance spectroscopy (BIS) and bioimpedance analysis (BIA) methods. *Med Eng Phys* 2008; **30**: 1257-1269 [PMID: 18676172 DOI: 10.1016/j.medengphy.2008.06.009]

30 **Kim M**, Kim H. Accuracy of segmental multi-frequency bioelectrical impedance analysis for assessing whole-body and appendicular fat mass and lean soft tissue mass in frail women aged 75 years and older. *Eur J Clin Nutr* 2013; **67**: 395-400 [PMID: 23388666 DOI: 10.1038/ejcn.2013.9]

31 **Lee DH**, Park KS, Ahn S, Ku EJ, Jung KY, Kim YJ, Kim KM, Moon JH, Choi SH, Park KS, Jang HC, Lim S. Comparison of Abdominal Visceral Adipose Tissue Area Measured by Computed Tomography with That Estimated by Bioelectrical Impedance Analysis Method in Korean Subjects. *Nutrients* 2015; **7**: 10513-10524 [PMID: 26694460 DOI: 10.3390/nu7125548]

32 **Esco MR**, Snarr RL, Leatherwood MD, Chamberlain NA, Redding ML, Flatt AA, Moon JR, Williford HN. Comparison of total and segmental body composition using DXA and multifrequency bioimpedance in collegiate female athletes. *J Strength Cond Res* 2015; **29**: 918-925 [PMID: 25353076 DOI: 10.1519/JSC.0000000000000732]

33 **Ling CH**, de Craen AJ, Slagboom PE, Gunn DA, Stokkel MP, Westendorp RG, Maier AB. Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population. *Clin Nutr* 2011; **30**: 610-615 [PMID: 21555168 DOI: 10.1016/j.clnu.2011.04.001]

34 **Ida S**, Watanabe M, Yoshida N, Baba Y, Umezaki N, Harada K, Karashima R, Imamura Y, Iwagami S, Baba H. Sarcopenia is a Predictor of Postoperative Respiratory Complications in Patients with Esophageal Cancer. *Ann Surg Oncol* 2015; **22**: 4432-4437 [PMID: 25862583 DOI: 10.1245/s10434-015-4559-3]

35 **Loria P**, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, Gasbarrini A, Loguercio C, Lonardo A, Marchesini G, Marra F, Persico M, Prati D, Baroni GS; NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. *Dig Liver Dis* 2010; **42**: 272-282 [PMID: 20171943 DOI: 10.1016/j.dld.2010.01.021]

**Footnotes**

**Institutional review board statement:** The study was approved by the Institutional Review Board of Seoul National University Boramae Medical Center (IRB No. 30-2020-054).

**Informed consent statement:** The subjects in this study were not required to give informed consent due to retrospective nature of the study and utilization of anonymous data utilization.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** August 11, 2020

**First decision:** October 18, 2020

**Article in press:** November 13, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** South Korea

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Aydin M, Gao BL, Sun X, Li Y **S-Editor:** Gao CC **L-Editor:** A **P-Editor:** Liu JH

**Figure Legends**



**Figure 1 Body morphometric evaluations of abdominal fat and muscle areas.** At the level of the inferior endplate of the L3 vertebra, a segmented axial computed tomography image showed the visceral fat area, subcutaneous fat area, and total abdominal muscle area (cm2), including all muscles on selected axial images, *i.e.*, psoas, paraspinals, transversus abdominis, rectus abdominis, quadratus lumborum, and internal and external obliques.



**Figure 2 Diagram of showing enrollment of the study population.** GBP: Gallbladder polyp.



**Figure 3 Correlation between the appendicular skeletal muscle mass measured by InBody 720 and the total abdominal muscle area measured by computed tomography scan.** ASM: Appendicular skeletal muscle mass; TAMA: Total abdominal muscle area; CT: Computed tomography.



**Figure 4 Correlation between the visceral fat area area measured by InBody 720 and computed tomography scan.** VFA: Visceral fat area; CT: Computed tomography.

**Table 1 Age distribution of the whole study population and subjects with gallbladder polyps**

|  |  |  |
| --- | --- | --- |
| **Age (yr)** | **Whole study population (*n* = 13498)** | **Subjects with gallbladder polyps (*n* = 1405)** |
| **Male** | **Female** | **Total** | **Male (%)** | **Female (%)** | **Total (%)** |
| < 30 | 497 | 664 | 1161 | 57 (11.5) | 34 (5.1) | 91 (7.8) |
| 30-39 | 1615 | 1590 | 3205 | 188 (11.6) | 128 (8.1) | 316 (9.9) |
| 40-49 | 1915 | 1206 | 3121 | 286 (14.9) | 134 (11.1) | 420 (13.5) |
| 50-59 | 1975 | 1512 | 3487 | 252 (12.8) | 123 (8.1) | 375 (10.8) |
| 60-69 | 1013 | 829 | 1842 | 88 (8.7) | 69 (8.3) | 157 (8.5) |
| ≥ 70 | 320 | 362 | 682 | 26 (8.1) | 20 (5.5) | 46 (6.7) |
| Total | 7335 | 6163 | 13498 | 897 (12.2) | 508 (8.2) | 1405 (10.4) |

**Table 2 Comparison of baseline characteristics between the subjects with and without gallbladder polyps**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristics** | **GBP group (*n* = 1405)** | **Control group (*n* = 2810)** | ***P* value** |
| Age (yr) | 46.84 ± 11.72 | 46.84 ± 11.72 | > 0.999 |
| Gender (male, %) | 897 (63.8%) | 1794 (63.8%) | > 0.999 |
| BMI (kg/m2) | 23.93 ± 3.04 | 23.94 ± 3.34 | 0.866 |
| Waist circumference (cm) | 84.30 ± 9.04 | 84.36 ± 9.48 | 0.844 |
| Visceral fat area (cm2) | 92.38 ± 32.51 | 94.52 ± 38.50 | 0.059 |
| ASM (kg) | 20.88 ± 5.22 | 20.76 ± 5.00 | 0.452 |
| Sarcopenia (%) | 87 (6.2%) | 215 (7.7%) | 0.087 |
| Hypertension (%) | 643 (45.8%) | 1273 (45.3%) | 0.793 |
| Diabetes (%) | 116 (8.3%) | 266 (9.5%) | 0.211 |
| Metabolic syndrome (%) | 307 (21.9%) | 626 (22.3%) | 0.783 |
| Fatty liver (%) | 643 (45.8%) | 1173 (41.7%) | 0.013 |
| Biochemistry |  |  |  |
| AST (IU/L) | 26.02 ± 17.18 | 27.80 ± 15.39 | 0.001 |
| ALT (IU/L) | 26.50 ± 22.88 | 29.02 ± 22.00 | 0.001 |
| Alkaline phosphatase (IU/L) | 66.18 ± 18.63 | 67.22 ± 19.48 | 0.099 |
| Gamma-glutamyltransferase (IU/L) | 31.00 ± 66.11 | 33.99 ± 46.29 | 0.089 |
| hs-CRP (mg/dL) | 0.16 ± 0.65 | 0.14 ± 0.38 | 0.249 |
| Total cholesterol (mg/dL) | 195.29 ± 36.24 | 197.40 ± 35.75 | 0.071 |
| Triglyceride (mg/dL) | 113.40 ± 73.21 | 117.28 ± 79.25 | 0.125 |
| HDL cholesterol (mg/dL) | 54.98 ± 13.52 | 55.09 ± 13.76 | 0.812 |
| CEA (ng/mL) | 1.63 ± 1.05 | 1.61 ± 1.00 | 0.574 |
| CA19-9 (IU/mL) | 10.59 ± 9.17 | 10.80 ± 11.32 | 0.548 |
| HBsAg (%) | 53 (3.9%) | 85 (3.1%) | 0.200 |
| HCV Ab (%) | 5 (0.4%) | 12 (0.4%) | > 0.999 |

Data are presented as mean± SD or number (%). GBP: Gallbladder polyp; BMI: Body mass index; ASM: Appendicular skeletal muscle mass; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; hs-CRP: High-sensitivity C-reactive protein; HDL: High-density lipoprotein; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; HBsAg: Hepatitis B virus surface antigen; HCV Ab: Hepatitis C virus antibody.

**Table 3 Univariable analysis of the risk factors for gallbladder polyps**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **OR** | **95%CI** | ***P* value** |
| BMI (kg/m2) |  |  |  |
| < 23 | 1.000 |  |  |
| ≥ 23, < 25 | 1.050 | 0.893-1.235 | 0.552 |
| ≥ 25 | 0.935 | 0.806-1.085 | 0.378 |
| Waist circumference (cm) |  |  |  |
| ≤ 90 (male), ≤ 80 (female) | 1.000 |  |  |
| > 90 (male), > 80 (female) | 1.057 | 0.925-1.208 | 0.413 |
| Hypertension |  |  |  |
| No | 1.000 |  |  |
| Yes | 1.019 | 0.896-1.159 | 0.776 |
| Diabetes |  |  |  |
| No | 1.000 |  |  |
| Yes | 0.861 | 0.685-1.081 | 0.197 |
| Metabolic syndrome |  |  |  |
| No | 1.000 |  |  |
| Yes | 0.975 | 0.836-1.139 | 0.753 |
| AST (IU/L) | 0.991 | 0.986-0.996 | 0.001 |
| ALT (IU/L) | 0.994 | 0.991-0.998 | 0.001 |
| Alkaline phosphatase (IU/L) | 0.997 | 0.994-1.001 | 0.100 |
| Gamma-glutamyltransferase (IU/L) | 0.999 | 0.997-1.000 | 0.090 |
| hs-CRP (mg/dL) | 1.076 | 0.944-1.226 | 0.273 |
| CEA (ng/mL) | 1.018 | 0.956-1.085 | 0.574 |
| CA19-9 (IU/mL) | 0.998 | 0.992-1.004 | 0.549 |
| HBsAg |  |  |  |
| No | 1.000 |  |  |
| Yes | 1.255 | 0.885-1.779 | 0.203 |
| HCV Ab |  |  |  |
| No | 1.000 |  |  |
| Yes | 0.835 | 0.294-2.375 | 0.736 |
| Total cholesterol (mg/dL) |  |  |  |
| < 200 | 1.000 |  |  |
| 200-240 | 0.948 | 0.824-1.091 | 0.459 |
| ≥ 240 | 0.875 | 0.708-1.080 | 0.213 |
| Triglyceride (mg/dL) |  |  |  |
| < 150 | 1.000 |  |  |
| ≥ 150 | 0.932 | 0.798-1.088 | 0.372 |
| HDL cholesterol (mg/dL) |  |  |  |
| > 40 (male), > 50 (female) | 1.000 |  |  |
| ≤ 40 (male), ≤ 50 (female) | 1.041 | 0.887-1.223 | 0.621 |
| Sarcopenia |  |  |  |
| No | 1.000 |  |  |
| Yes | 0.797 | 0.616-1.031 | 0.084 |
| Visceral fat area (cm2) |  |  |  |
| Quartile I (male < 81.8, female < 55.2) | 1.000 |  |  |
| Quartile II (male 81.8-100.8, female 55.2-71.6) | 1.069 | 0.890-1.283 | 0.477 |
| Quartile III (male 100.8-121.8, female 71.6-92.5) | 0.951 | 0.793-1.140 | 0.585 |
| Quartile IV (male > 121.8, female > 92.5) | 0.853 | 0.721-1.010 | 0.066 |
| Fatty liver |  |  |  |
| No | 1.000 |  |  |
| Yes | 1.178 | 1.035-1.340 | 0.013 |

OR: Odds ratio; CI: Confidence level; BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; hs-CRP: High-sensitivity C-reactive protein; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; HBsAg: Hepatitis B virus surface antigen; HCV Ab: Hepatitis C virus antibody; HDL: High-density lipoprotein.

**Table 4 Multivariable analysis of the risk factors for gallbladder polyps**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **OR** | **95% CI** | ***P* value** |
| ALT (IU/L) | 0.993 | 0.989-0.996 | < 0.001 |
| Fatty liver |  |  |  |
| No | 1.000 |  |  |
| Yes | 1.413 | 1.218-1.638 | < 0.001 |

OR: Odds ratio; CI: Confidence level; BMI: Body mass index; ALT: Alanine aminotransferase.

**Table 5 Multivariable analysis of the association between gallbladder polyps and fatty liver grades according to gallbladder polyp size**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **OR** | **95% CI** | ***P* value** |
| Total population |  |  |  |
| The presence of fatty liver | 1.413 | 1.218-1.638 | < 0.001 |
| Fatty liver grade |  |  |  |
| No | 1.000 |  | < 0.0011 |
| Mild | 1.338 | 1.141-1.570 | < 0.001 |
| Moderate to severe | 1.631 | 1.317-2.020 | < 0.001 |
| GBP ≥ 5 mm |  |  |  |
| The presence of fatty liver | 1.629 | 1.335-1.988 | < 0.001 |
| Fatty liver grade |  |  |  |
| No | 1.000 |  | < 0.0011 |
| Mild | 1.523 | 1.228-1.888 | < 0.001 |
| Moderate to severe | 2.137 | 1.662-2.749 | < 0.001 |
| GBP < 5 mm |  |  |  |
| The presence of fatty liver | 1.318 | 1.085-1.602 | 0.005 |
| Fatty liver grade |  |  |  |
| No | 1.000 |  | 0.0381 |
| Mild | 1.315 | 1.072-1.613 | 0.009 |
| Moderate to severe | 1.332 | 0.990-1.792 | 0.058 |

1*P* value for the test of trend of odds. OR: Odds ratio; CI: Confidence level; GBP: Gallbladder polyp.